JP2024075737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024075737A5 JP2024075737A5 JP2024048842A JP2024048842A JP2024075737A5 JP 2024075737 A5 JP2024075737 A5 JP 2024075737A5 JP 2024048842 A JP2024048842 A JP 2024048842A JP 2024048842 A JP2024048842 A JP 2024048842A JP 2024075737 A5 JP2024075737 A5 JP 2024075737A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antibody variant
- combination
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 13
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 12
- 239000003981 vehicle Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 102000052645 human CD38 Human genes 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008177 pharmaceutical agent Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 239000001825 Polyoxyethene (8) stearate Substances 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101710095468 Cyclase Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000005883 trogocytosis Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862697730P | 2018-07-13 | 2018-07-13 | |
| US62/697,730 | 2018-07-13 | ||
| US201962848874P | 2019-05-16 | 2019-05-16 | |
| US62/848,874 | 2019-05-16 | ||
| PCT/EP2019/069028 WO2020012036A1 (en) | 2018-07-13 | 2019-07-15 | Variants of cd38 antibody and uses thereof |
| JP2021500814A JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500814A Division JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024075737A JP2024075737A (ja) | 2024-06-04 |
| JP2024075737A5 true JP2024075737A5 (https=) | 2024-10-17 |
Family
ID=67396922
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500814A Active JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
| JP2024048842A Pending JP2024075737A (ja) | 2018-07-13 | 2024-03-26 | Ｃｄ３８抗体のバリアントおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500814A Active JP7526717B2 (ja) | 2018-07-13 | 2019-07-15 | Ｃｄ３８抗体のバリアントおよびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20200017600A1 (https=) |
| EP (1) | EP3820900A1 (https=) |
| JP (2) | JP7526717B2 (https=) |
| KR (1) | KR20210031932A (https=) |
| CN (2) | CN112513082B (https=) |
| AU (1) | AU2019300223A1 (https=) |
| BR (1) | BR112020026432A2 (https=) |
| CA (1) | CA3106146A1 (https=) |
| CL (1) | CL2021000066A1 (https=) |
| CO (1) | CO2021001544A2 (https=) |
| CR (1) | CR20210081A (https=) |
| DO (2) | DOP2021000006A (https=) |
| EC (1) | ECSP21010092A (https=) |
| IL (1) | IL279937A (https=) |
| MA (1) | MA53122A (https=) |
| MX (1) | MX2020013631A (https=) |
| MY (1) | MY205398A (https=) |
| PE (1) | PE20211858A1 (https=) |
| PH (1) | PH12021550054A1 (https=) |
| SG (1) | SG11202012993SA (https=) |
| TW (1) | TW202019518A (https=) |
| WO (1) | WO2020012036A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| MA53122A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
| KR20220130724A (ko) * | 2020-01-16 | 2022-09-27 | 젠맵 에이/에스 | Cd38 항체의 제제 및 그의 용도 |
| KR20230018439A (ko) * | 2020-06-02 | 2023-02-07 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물 |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
| WO2023044346A2 (en) | 2021-09-14 | 2023-03-23 | Ausper Biopharma Co., Ltd. | Vaccines for coronavirus prevention and treatment |
| WO2023045859A1 (zh) * | 2021-09-23 | 2023-03-30 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| US20230136301A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
| CN114409788B (zh) * | 2022-03-04 | 2022-10-04 | 四川大学华西医院 | 抗cd38的抗体及其应用 |
| US20250382378A1 (en) | 2022-10-31 | 2025-12-18 | Genmab A/S | Cd38 antibodies and uses thereof |
| WO2024131849A1 (zh) * | 2022-12-21 | 2024-06-27 | 非同（成都）生物科技有限公司 | Cd38单克隆抗体及其应用 |
| JP2026510999A (ja) | 2023-03-21 | 2026-04-10 | バイオグラフ ５５，インク． | Ｃｄ１９／ｃｄ３８多重特異性抗体 |
| CN120965865B (zh) * | 2025-10-15 | 2026-01-16 | 内蒙古盛健生物科技有限责任公司 | 一种用于特异性治疗奶山羊羔羊口疮的抗体及其应用 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US835A (en) | 1838-07-12 | X i i i x | ||
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2065299C (en) | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP3569245A1 (en) | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| EP3424951A1 (en) | 2007-06-21 | 2019-01-09 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| EP2376109B1 (en) | 2008-12-19 | 2019-01-23 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| EP2507381A4 (en) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| DK2580243T3 (da) * | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| MX340556B (es) | 2010-08-24 | 2016-07-14 | Roche Glycart Ag | Anticuerpos biespecificos activables. |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| EP2729496B8 (en) * | 2011-07-06 | 2017-10-18 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| BR112015000167B1 (pt) * | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| JP2015527366A (ja) | 2012-08-20 | 2015-09-17 | グリックニック インコーポレイテッド | 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子 |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| DK2970456T3 (da) | 2013-03-14 | 2021-07-05 | Translate Bio Inc | Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| TWI648401B (zh) * | 2013-07-31 | 2019-01-21 | 安美基公司 | 生長分化因子１５（ｇｄｆ－１５）構築體 |
| CN106255704A (zh) | 2014-04-16 | 2016-12-21 | Ucb生物制药私人有限公司 | 多聚体Fc蛋白 |
| EP4667492A3 (en) * | 2015-05-26 | 2026-04-15 | Ramot at Tel-Aviv University Ltd. | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes |
| HRP20240338T1 (hr) * | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| MA43365A (fr) * | 2015-12-01 | 2018-10-10 | Genmab Bv | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CN109563511A (zh) | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
| WO2018031258A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
| EP3559250A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
| MX2019006123A (es) | 2016-12-21 | 2019-08-12 | Hoffmann La Roche | Metodo para glicomanipulacion in vitro de anticuerpos. |
| WO2018114877A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
| US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| MA53122A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
-
2019
- 2019-07-15 MA MA053122A patent/MA53122A/fr unknown
- 2019-07-15 BR BR112020026432-6A patent/BR112020026432A2/pt unknown
- 2019-07-15 KR KR1020217003848A patent/KR20210031932A/ko not_active Ceased
- 2019-07-15 MY MYPI2020006631A patent/MY205398A/en unknown
- 2019-07-15 SG SG11202012993SA patent/SG11202012993SA/en unknown
- 2019-07-15 EP EP19742548.1A patent/EP3820900A1/en active Pending
- 2019-07-15 JP JP2021500814A patent/JP7526717B2/ja active Active
- 2019-07-15 CN CN201980047066.7A patent/CN112513082B/zh active Active
- 2019-07-15 AU AU2019300223A patent/AU2019300223A1/en active Pending
- 2019-07-15 TW TW108124908A patent/TW202019518A/zh unknown
- 2019-07-15 PE PE2021000038A patent/PE20211858A1/es unknown
- 2019-07-15 CR CR20210081A patent/CR20210081A/es unknown
- 2019-07-15 CA CA3106146A patent/CA3106146A1/en active Pending
- 2019-07-15 MX MX2020013631A patent/MX2020013631A/es unknown
- 2019-07-15 US US16/512,206 patent/US20200017600A1/en not_active Abandoned
- 2019-07-15 CN CN202511041049.6A patent/CN120865412A/zh active Pending
- 2019-07-15 WO PCT/EP2019/069028 patent/WO2020012036A1/en not_active Ceased
-
2020
- 2020-02-10 US US16/786,563 patent/US20200165352A1/en not_active Abandoned
-
2021
- 2021-01-04 IL IL279937A patent/IL279937A/en unknown
- 2021-01-08 CL CL2021000066A patent/CL2021000066A1/es unknown
- 2021-01-08 PH PH12021550054A patent/PH12021550054A1/en unknown
- 2021-01-11 DO DO2021000006A patent/DOP2021000006A/es unknown
- 2021-02-10 CO CONC2021/0001544A patent/CO2021001544A2/es unknown
- 2021-02-11 EC ECSENADI202110092A patent/ECSP21010092A/es unknown
-
2024
- 2024-01-23 US US18/420,021 patent/US20240317881A1/en active Pending
- 2024-03-26 JP JP2024048842A patent/JP2024075737A/ja active Pending
- 2024-10-25 DO DO2024000217A patent/DOP2024000217A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024075737A5 (https=) | ||
| JP2021524276A5 (https=) | ||
| Lou et al. | Antibody variable region engineering for improving cancer immunotherapy | |
| JP2025163055A5 (https=) | ||
| CN103030695B (zh) | 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物 | |
| JP2021514664A5 (https=) | ||
| JP2022008382A5 (https=) | ||
| JP2021531754A5 (https=) | ||
| EP3885367A1 (en) | Anti-her2/pd1 bispecific antibody | |
| JP2020501531A5 (https=) | ||
| EP3759229A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer | |
| JPWO2019173420A5 (https=) | ||
| CN104334579A (zh) | 抗c-met抗体及其用途 | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022526841A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| JP2022527173A5 (https=) | ||
| JP2020530770A5 (https=) | ||
| JPWO2020012036A5 (https=) | ||
| JP2005515967A5 (https=) | ||
| JPWO2023288241A5 (https=) | ||
| JPWO2020210067A5 (https=) | ||
| KR20220102114A (ko) | Cd55에 대한 신규 항체 및 이의 용도 | |
| JPWO2020218951A5 (https=) | ||
| JP6887944B2 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 |